| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Unit for the Study of Iron Metabolism, University of Modena and Reggio Emilia, Via del Pozzo 71, 41100 Modena, Italy
Iron is essential for fundamental cell functions but is also a catalyst for chemical reactions involving free radical formation, potentially leading to oxidative stress and cell damage. Cellular iron levels are therefore carefully regulated to maintain an adequate substrate while also minimizing the pool of potentially toxic "free iron." The main control of body iron homeostasis in higher organisms is placed in the duodenum, where dietary iron is absorbed, whereas no controlled means of eliminating unwanted iron have evolved in mammals. Hereditary hemochromatosis, the prototype of deregulated iron homeostasis in humans, is due to inappropriately increased iron absorption and is commonly associated to a mutated HFE gene. The HFE protein is homologous to major histocompatibility complex class I proteins but is not an iron carrier, whereas biochemical and cell biological studies have shown that the transferrin receptor, the main protein devoted to cellular uptake of transferrin iron, interacts with HFE. This review focuses on recent advances in iron research and presents a model of HFE function in iron metabolism.
HFE; transferrin; transferrin receptor; divalent metal transport 1; ferroportin1/IREG1/MTP1
This article has been cited by other articles:
|
|
 |
|
  P. Thankachan, T. Walczyk, S. Muthayya, A. V Kurpad, and R. F Hurrell Iron absorption in young Indian women: the interaction of iron status with the influence of tea and ascorbic acid Am. J. Clinical Nutrition, April 1, 2008; 87(4): 881 - 886. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Weiss and L. T. Goodnough Anemia of Chronic Disease N. Engl. J. Med., March 10, 2005; 352(10): 1011 - 1023. [Full Text] [PDF]
|
|
|
|
 |
|
 T Kelleher, E Ryan, S Barrett, M Sweeney, V Byrnes, C O'Keane, and J Crowe Increased DMT1 but not IREG1 or HFE mRNA following iron depletion therapy in hereditary haemochromatosis Gut, August 1, 2004; 53(8): 1174 - 1179. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H Kulaksiz, S G Gehrke, A Janetzko, D Rost, T Bruckner, B Kallinowski, and W Stremmel Pro-hepcidin: expression and cell specific localisation in the liver and its regulation in hereditary haemochromatosis, chronic renal insufficiency, and renal anaemia Gut, May 1, 2004; 53(5): 735 - 743. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. G. Gehrke, H. Kulaksiz, T. Herrmann, H.-D. Riedel, K. Bents, C. Veltkamp, and W. Stremmel Expression of hepcidin in hereditary hemochromatosis: evidence for a regulation in response to the serum transferrin saturation and to non-transferrin-bound iron Blood, July 1, 2003; 102(1): 371 - 376. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. M. Qian, H. Li, H. Sun, and K. Ho Targeted Drug Delivery via the Transferrin Receptor-Mediated Endocytosis Pathway Pharmacol. Rev., December 1, 2002; 54(4): 561 - 587. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |
